Lexaria Bioscience Corp. (NASDAQ: LEXX) Using Patented DehydraTECH(TM) Technology to Fight America’s Silent Killer – Hypertension

  • Three out of four adults living with hypertension do not have the condition under control, putting them at risk for other serious complications
  • Lexaria’s proposed therapy for hypertension is the highly efficient DehydraTECH-CBD, which has presented with no serious adverse side effects in test participants
  • Dominated by the North American market, the global antihypertension drug market accounted for $22,557 million in 2018 and is expected to reach $28,797 million by 2026

In the United States, over 121.5 million adults are affected by high blood pressure – with statistics stacked against people of color, those with a family history of high blood pressure, heart disease, stroke, or kidney disease, and women who experienced blood pressure problems during pregnancy. According to the American Heart Association, high blood pressure is defined as a systolic pressure of 130 or higher and a diastolic pressure of 80 or higher that stays high over a period of time (https://cnw.fm/dbCLN).

For some, managing high blood pressure is as simple as changing daily habits or being proactive about monitoring it if there is a history or predisposition to the disease. Early detection can protect the brain, reducing the risk of stroke, dementia, and other vascular diseases that affect the brain. Although high blood pressure is not the only risk factor associated, being conscious of it can help preserve the brain’s blood vessels. Unfortunately, three out of four adults do not have their high blood pressure under control, creating an unmet need in the hypertension treatment market.

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is using its patented DehydraTECH(TM) technology to address the unmet needs of adults with high blood pressure (hypertension). DehydraTECH is a patented drug delivery technology that improves the oral administration of Active Pharmaceutical Ingredients (“APIs”). The benefits of using DehydraTECH-enabled APIs include the following:

  • Improvement of onset speed – effects of the drug are felt in minutes
  • Masked unwanted tastes – eliminates the need for sugar-filled edibles
  • Increased bioavailability – the technology is more effective at delivering the drug into the bloodstream
  • Increased brain absorption – testing has seen up to 27x improvement in the amount of the drug crossing the blood-brain barrier
  • Reduction in drug administration costs – the higher ratio of the drug being delivered is expected to lower the overall costs of administration

Lexaria’s initial focus on hypertension has been its DehydraTECH-CBD, which is currently in the IND enabling studies phase and is actively developing lead product pipeline candidates. The advanced hypertension program has delivered positive results with no serious adverse effects, with the most recent being completed in 2021, with 16 participants exhibiting a reduction of attenuated pulmonary artery systolic pressure of approximately 5 mmHg, or 41% overall, in male participants. The company’s corporate presentation lists all of the results – from 2018-2021 (https://cnw.fm/0by1r). Results are pending from Lexaria’s largest ever human clinical trial, where dosing completed in July.

According to Allied Market Research, the global antihypertension drug market accounted for $22,557 million in 2018 and is expected to reach $28,797 million by 2026, growing at a CAGR of 3.1% from 2019 to 2026. North America dominates the majority of the drug market. The market’s growth is expected due to the prevalence of hypertension across the globe and the interest in maintaining healthier lifestyles in the wake of the COVID-19 pandemic (https://cnw.fm/5vqaT). 

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
303.498.7722 Office

CannabisNewsWire is part of the InvestorBrandNetwork.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s